Wall Street analysts forecast that Boston Scientific Co. (NYSE:BSX) will post earnings of $0.36 per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Boston Scientific’s earnings, with the lowest EPS estimate coming in at $0.35 and the highest estimate coming in at $0.36. Boston Scientific posted earnings of $0.33 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 9.1%. The firm is expected to announce its next quarterly earnings results on Wednesday, April 24th.

On average, analysts expect that Boston Scientific will report full-year earnings of $1.56 per share for the current fiscal year, with EPS estimates ranging from $1.54 to $1.58. For the next financial year, analysts forecast that the firm will post earnings of $1.80 per share, with EPS estimates ranging from $1.72 to $1.88. Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Boston Scientific.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 6th. The medical equipment provider reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.02. The company had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.57 billion. Boston Scientific had a net margin of 17.01% and a return on equity of 25.92%. Boston Scientific’s revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.34 EPS.

BSX has been the topic of a number of research analyst reports. Guggenheim reissued a “buy” rating and issued a $48.00 price target on shares of Boston Scientific in a research note on Friday, February 8th. Argus boosted their price target on shares of Boston Scientific from $43.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 13th. Credit Suisse Group initiated coverage on shares of Boston Scientific in a research note on Monday, December 17th. They issued an “outperform” rating and a $42.00 price target on the stock. Canaccord Genuity reissued a “buy” rating and issued a $45.00 price target on shares of Boston Scientific in a research note on Monday, February 11th. Finally, SunTrust Banks reissued a “buy” rating and issued a $47.00 price target on shares of Boston Scientific in a research note on Friday, February 8th. Three equities research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $40.54.

In related news, CFO Daniel J. Brennan sold 22,438 shares of the company’s stock in a transaction that occurred on Thursday, February 14th. The shares were sold at an average price of $39.57, for a total transaction of $887,871.66. Following the sale, the chief financial officer now directly owns 279,183 shares of the company’s stock, valued at approximately $11,047,271.31. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kevin J. Ballinger sold 14,740 shares of the company’s stock in a transaction that occurred on Thursday, January 3rd. The stock was sold at an average price of $33.65, for a total transaction of $496,001.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 361,138 shares of company stock worth $14,316,850. 0.73% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. We Are One Seven LLC purchased a new stake in Boston Scientific during the 4th quarter worth approximately $27,000. Athena Capital Advisors LLC purchased a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $28,000. Ipswich Investment Management Co. Inc. purchased a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $28,000. CWM LLC increased its position in shares of Boston Scientific by 54.3% in the 4th quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 359 shares during the last quarter. Finally, West Oak Capital LLC increased its position in shares of Boston Scientific by 40.0% in the 4th quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 300 shares during the last quarter. 91.89% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Boston Scientific stock traded down $0.35 on Wednesday, reaching $37.49. The company had a trading volume of 4,669,539 shares, compared to its average volume of 7,320,704. The company has a market capitalization of $52.17 billion, a price-to-earnings ratio of 25.50, a price-to-earnings-growth ratio of 2.15 and a beta of 0.88. Boston Scientific has a 52-week low of $26.42 and a 52-week high of $41.00. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.54 and a current ratio of 0.76.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: Analyst Ratings Trading

Get a free copy of the Zacks research report on Boston Scientific (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.